|
Teva Announces Approval Of Generic Lexapro® Tablets |
|
|
|
23 May 2006 |
JERUSALEM, Israel | May 22, 2006 | Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration has granted final approval for the Company’s Abbreviated New Drug Application (ANDA) to market its generic version of Forest Laboratories, Inc.’s Lexapro® (Escitalopram Oxalate) Tablets, 5 mg, 10 mg and 20 mg.
Teva’s AB-rated Escitalopram Oxalate Tablets are indicated for the treatment of depression. Teva is currently in patent litigation concerning this product in the U.S. District Court for the District of Delaware. A suit was brought against Teva’s subsidiary IVAX in September 2003 involving its paragraph IV certification to U.S. Patent No. RE34,712.
A trial was held in March 2006 and the post-trial briefing period ended on May 19th. Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 20 pharmaceutical companies in the world and is the leading generic pharmaceutical company. The company develops, manufactures and markets generic and innovative human pharmaceuticals and active pharmaceutical ingredients, as well as animal health pharmaceutical products. Close to 90% of Teva’s sales are in North America and Europe.
SOURCE: Teva, Ltd |
